Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects.

Despite a decreasing trend in NGS costs during the last few years, the costs of big pan-cancer panels are not affordable for routine patient surveillance, and big panel sizes could affect the sensitivity of marker identification and decrease the signal-to-noise ratio ( Cohen et al., 2018 ).

also in 47,180 other papers